PLAVIX SUITS HIGHLIGHT WAR OVER GENERICS

The marketers of the world's second-largest-selling drug dodged a major threat to their revenues two months ago by reaching a deal to keep a generic competitor at bay until at least 2011.

The Post and Courier (http://www.charleston.net/stories/?newsID=89851§ion=business)